Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model

被引：0
作者：
Ryan Thaliffdeen
Anthony Yu
Karen Rascati
机构：
[1] The University of Texas at Austin,Health Outcomes Division, College of Pharmacy
来源：
Clinical Drug Investigation | 2024年 / 44卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：209 / 217
页数：8
相关论文
共 50 条
[31]   Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective [J].
Tsai, Naoky ;
Jeffers, Lennox ;
Cragin, Lael ;
Sorensen, Sonja ;
Su, Wenqing ;
Rosenblatt, Lisa ;
Tang, Hong ;
Hebden, Tony ;
Juday, Timothy .
CLINICOECONOMICS AND OUTCOMES RESEARCH, 2012, 4 :227-235
[32]   Tremelimumab plus durvalumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: a cost-effectiveness analysis from the US payer perspective [J].
Cheng, Shuqiao ;
Li, Bin ;
Tang, Lanhua ;
Liu, Shao ;
Xiao, Jian .
BMJ OPEN, 2025, 15 (04)
[33]   Cost-effectiveness of durvalumab plus tremelimumab in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer from the US healthcare sector's and societal perspectives [J].
Gan, Yena ;
Shi, Fenghao ;
Zhu, He ;
Li, Huangqianyu ;
Han, Sheng ;
Li, Duoduo .
FRONTIERS IN PHARMACOLOGY, 2024, 15
[34]   The cost-effectiveness of pioglitazone compared with rosiglitazone: An economic evaluation projecting results from a clinical study into the future using a valid and reliable economic model from a third party payer perspective in the USA [J].
Minshall, M. ;
St. Charles, M. ;
Pandya, B. ;
Baran, R. W. .
VALUE IN HEALTH, 2007, 10 (06) :A259-A259
[35]   SECUKINUMAB IS DOMINANT VS. TNF-INHIBITORS IN THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM A TURKISH COST-EFFECTIVENESS MODEL [J].
Sarioz, R. ;
Ozdemir, O. ;
Direk, S. ;
Sezen, Cavusoglu S. ;
Barutcugil, M. .
VALUE IN HEALTH, 2017, 20 (09) :A534-A534
[36]   Cost-Effectiveness of Tight Control for Crohn's Disease With Adalimumab-Based Treatment: Economic Evaluation of the CALM Trial From a Canadian Perspective [J].
Lakatos, Peter L. ;
Kaplan, Gilaad G. ;
Bressler, Brian ;
Khanna, Reena ;
Targownik, Laura ;
Jones, Jennifer ;
Rahal, Yasmine ;
McHugh, Kevin ;
Panaccione, Remo .
JOURNAL OF THE CANADIAN ASSOCIATION OF GASTROENTEROLOGY, 2022, 5 (04) :169-176
[37]   COST-EFFECTIVENESS ANALYSIS OF TISAGENLECLEUCEL USING LONG-TERM SURVIVAL OUTCOMES IN TREATING ADULT PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA FROM US SOCIETAL PERSPECTIVE [J].
Choe, J. ;
Abdel-Azim, H. ;
Abou-el-Enein, M. ;
Padula, W. .
VALUE IN HEALTH, 2022, 25 (07) :S361-S361
[38]   COMPARING COSTS AND OUTCOMES BETWEEN COBLATION TECHNOLOGY AND MECHANICAL DEBRIDEMENT IN THE TREATMENT OF KNEE CARTILAGE LESIONS-A COST-EFFECTIVENESS ANALYSIS FROM A US PAYER PERSPECTIVE [J].
Adeyemi, A. ;
Nherera, L. ;
Trueman, P. ;
Delhougne, G. .
VALUE IN HEALTH, 2017, 20 (09) :A735-A735
[39]   An evaluation of the clinical and cost-effectiveness of combination chemotherapy with gemcitabine plus paclitaxel for the treatment of metastatic breast cancer (MBC) in the UK from an NHS perspective. [J].
Bhalla, S. ;
Hibbert, C. ;
Chetty, M. ;
Poole, C. ;
Miles, D. ;
Coleman, R. ;
Bruce, G. ;
Beard, S. ;
Watkins, J. .
BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 :S232-S232
[40]   COST-EFFECTIVENESS ANALYSIS OF INTRODUCING SEMAGLUTIDE ORAL AND SEMAGLUTIDE INJECTION FOR THE TREATMENT OF DIABETES TYPE II FROM THE PERSPECTIVE OF THE SAUDI MOH USING BESPOKE UTILITY MAPPING METHOD [J].
Al Jedai, A. ;
AL-Mudaiheem, H. ;
Alluhidan, M. ;
Almogbel, Y. ;
Alowairdhi, M. ;
AlMasouad, R. ;
AlTowaijiri, A. A. ;
AlAbali, N. A. ;
Awad, N. A. ;
Ojeil, R. ;
Hassan, M. .
VALUE IN HEALTH, 2024, 27 (12) :S67-S67
12345